Miguel Ángel Álvarez-Avitia

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Robert I. Haddad, Kevin J. Harrington, Makoto Tahara et al. · Journal of Clinical Oncology · 2022 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Randomized Phase II Trial of All-<i>Trans</i>-Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Non–Small-Cell Lung Cancer

Óscar Arrieta, Claudia Haydée González-De la Rosa, Elena Aréchaga-Ocampo et al. · Journal of Clinical Oncology · 2010 · 126 citations · Full text

Medicine, Oncology, Pharmacology +17

Rapid recovery of a SARS-CoV-2–infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma

Estefanía Mira, Oscar Yarce, Consuelo Ortega et al. · The Journal of Allergy and Clinical Immunology In Practice · 2020 · 87 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success

Albert Seoane, Genís Carrasco, Lluís Cabré et al. · The British Journal of Psychiatry · 1997 · 74 citations

Medicine, Pharmacology, Pharmacotherapy +13

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero et al. · Blood · 2019 · 62 citations

Medicine, Hematology, Oncology +11